Breaking News Instant updates and real-time market news.

CRM

Salesforce

, SDS

UltraShort S&P500 ProShares

09:40
10/05/16
10/05
09:40
10/05/16
09:40

Unusually active option classes on open October 5th

Unusual total active option classes on open include: Salesforce.com (CRM), ProShares UltraShort S&P 500 (SDS), Financial Sector SPDR (XLF), Twitter (TWTR), Micron (MU), Transocean (RIG), iShares Russell 2000 Index Fund (IWM), Las Vegas Sands (LVS), Netflix (NFLX), and Deutsche Bank (DB).

CRM

Salesforce

SDS

UltraShort S&P500 ProShares

XLF

Financial Select Sector

TWTR

Twitter

MU

Micron

$17.80

0.07 (0.39%)

RIG

Transocean

IWM

iShares Trust Russell 2000 Index Fund

LVS

Las Vegas Sands

NFLX

Netflix

$102.34

-0.29 (-0.28%)

DB

Deutsche Bank

  • 05

    Oct

  • 17

    Oct

  • 23

    Oct

  • 29

    Nov

  • 30

    Nov

CRM Salesforce

10/05/16
WEDB
10/05/16
NO CHANGE
WEDB
Outperform
Twitter worries obscuring positive trends for Salesforce, says Wedbush
Wedbush analyst Steve Koenig said his industry and partner checks don't point to any secular headwinds for Salesforce's (CRM) business, adding that the company gave several reassuring metrics on its progress in cross-selling, growing deal sizes, and expanding its large account base at its investor day event at the Dreamforce conference. At the investor day, management acknowledged conjecture about Salesforce trying to buy Twitter (TWTR), but deflected comments, with CFO Mark Hawkins suggesting that CEO Marc Benioff's Q&A session Wednesday afternoon may be a better forum for soliciting comments, noted Koenig. The analyst, who remains constructive on Salesforce as long as the company doesn't buy Twitter, keeps an Outperform rating on the shares.
10/05/16
BOFA
10/05/16
NO CHANGE
Target $100
BOFA
Buy
Salesforce acquisition of Twitter 'quite low,' says BofA/Merrill
BofA/Merrill analyst Kash Rangan said the probability of Salesforce (CRM) acquiring Twitter (TWTR) is "quite low." The analyst does not believe Salesforce would materially dilute its shareholders with such a risky deal and expects the CEO to provide clarity on the thought process behind core software acquisitions versus media at today's Q&A session. Rangan rates Salesforce a Buy with a $100 price target on shares.
10/05/16
BMOC
10/05/16
NO CHANGE
BMOC
Outperform
BMO says Salesforce's positive messages overshadowed by Twitter speculation
BMO Capital analyst Keith Bachman said the positive themes laid out by Salesforce (CRM) management at the company's Dreamforce event, such as guidance to reach $10B in FY18 revenues without inorganic sources of revenue, would traditionally help the stock. However, news reports, including the most recent from the Wall Street Journal, indicating that the company may buy Twitter (TWTR), will outweigh the "positive messages" of the event. If Salesforce were to buy Twitter, the stock would move meaningfully lower, Bachman predicted, but he also wonders if strategic buyers would then potentially consider buying Salesforce. The firm keeps its Outperform rating on Salesforce shares.
10/05/16
STFL
10/05/16
NO CHANGE
Target $93
STFL
Buy
Stifel still sees Salesforce acquisition of Twitter as 'highly unlikely'
Stifel analyst Tom Roderick notes that Salesforce (CRM) kicked off its annual Dreamforce User Conference yesterday amid reports that the company may be a potential suitor for Twitter (TWTR). The analyst still believes that a Salesforce acquisition of Twitter is "highly unlikely," both from a logistical standpoint and from a business model fit perspective. Regarding fundamentals, Roderick continues to view Salesforce as a leading driver of the enterprise shift to the Cloud, and sees no reason why that shouldn't continue to play out in the second half of 2017, in spite of recent concerns about the mid-year slowdown. He reiterates a Buy rating and $93 price target on Salesforce's shares.
SDS UltraShort S&P500 ProShares

XLF Financial Select Sector

TWTR Twitter

MU Micron
$17.80

0.07 (0.39%)

10/05/16
EVER
10/05/16
NO CHANGE
Target $25
EVER
Buy
Micron guidance conservative, buy on weakness, says Evercore ISI
Evercore ISI analyst CJ Muse said Micron's guidance is conservative and continues to believe there will be a DRAM shortage situation in CY17 that will drive earnings power to $2-$3 including SBC. Muse recommends adding to Micron positions on weakness and reiterates his Buy rating and $25 price target.
10/05/16
COWN
10/05/16
NO CHANGE
Target $19
COWN
Outperform
Micron interesting on a pullback, says Cowen
Cowen analyst Timothy Arcuri said Micron's guidance was troubling but he still sees a positive bias as DRAM supply/demand remains the first order driver for the company and industry capital expenditure is still being diverted to 3D NAND. Arcuri believes the shares will be interesting on a pullback, but said it is hardly his favorite idea. Arcuri maintained his Outperform rating and $19 price target on Micron shares.
10/05/16
STFL
10/05/16
NO CHANGE
Target $22
STFL
Buy
Micron only at start of up cycle, says Stifel
Stifel analyst Kevin Cassidy raised his price target for Micron Technology to $22 from $20, saying the company last night delivered a "solid beat" to his expectations and the consensus forecast. The company's non-GAAP EPS guidance "has some controversy" and may cause some weakness in the shares, added Cassidy. However, he would be a buyer on the weakness, citing his view that Micron's up cycle is only at its beginning. The firm keeps its Buy rating on Micron shares.
10/05/16
SUSQ
10/05/16
NO CHANGE
Target $21
SUSQ
Positive
Micron investors should focus on DRAM fundamentals, says Susquehanna
Susquehanna analyst Mehdi Hosseini noted Micron reported better than expected Q4 results driven by higher revenues. The analyst said the company guidance is below the buy-side expectation and he believes they are still challenged by converting planar to 3D NAND. Hosseini said Micron investors should focus on improving DRAM fundamentals as the better environment bodes well for the company's minority interest income and should help free cash flow. Hosseini reiterated his Buy rating and raised his price target to $21 from $20 on Micron shares.
RIG Transocean

10/04/16
HOWW
10/04/16
UPGRADE
Target $14
HOWW
Outperform
Transocean upgraded to Outperform from Sector Perform at Scotia Howard Weil
Scotia Howard Weil analyst Blake Hancock upgraded Transocean to Outperform and raised its price target to $14 from $12.
09/23/16
FBCO
09/23/16
UPGRADE
FBCO
Neutral
Transocean upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Gregory Lewis is upgraded Transocean to Neutral and raised its price target to $8 from $5. Lewis said management has been extending Transocean's duration and expects the company's diverse foot print and relationships to drive increased contracts.
09/19/16
SUSQ
09/19/16
NO CHANGE
SUSQ
Susquehanna lowers price targets on several offshore drillers
Susquehanna analyst Charles Minervino lowered his estimates and price targets on offshore drillers by an average of 17%, citing lower crude prices, extended softness in new contracting activity, and expectations for a prolonged period of low dayrates. Minervino lowered his price target on Neutral rated companies Atwood Oceanics (ATW) to $7 from $11, Diamond Offshore (DO) to $16 from $18, Ensco (ESV) to $7 from $8, Noble Corp. (NE) to $5 from $6, Rowan (RDC) to $12 from $14, and Transocean (RIG) to $10 from $11.
09/15/16
09/15/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Hold from Sell at Canaccord with analyst Alex Brooks citing valuation. 2. Dick's Sporting (DKS) upgraded to Outperform from Perform at Oppenheimer analyst Brian Nagel citing the potential for better near-term sales trends as "weaker players" in sporting goods retail fail. 3. Akorn (AKRX) upgraded to Overweight from Neutral at Piper Jaffray with analyst David Amsellem saying volume trends across the company's commercial portfolio suggests the base business is "on sustainable footing." 4. Petrobras (PBR) upgraded to Neutral from Underperform at Macquarie with analyst Giacomo Romeo saying near-term liquidity is less concerning after recent divestitures, an improved political outlook, and the re-gained access to the bond market. 5. bluebird bio (BLUE) upgraded to Conviction Buy from Buy at Goldman with analyst Salveen Richter saying he expects Gen2 data versus Gen1 data at the October 13 R&D day to show substantial efficacy improvements, which is underappreciated by the Street, a full LentiGlobin update at ASH scheduled for December 3-6, the unveiling of the CAR T/gene editing programs, and two pivotal readouts in mid-17 that will result in a transition to commercial focus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
IWM iShares Trust Russell 2000 Index Fund

LVS Las Vegas Sands

09/14/16
ARGS
09/14/16
UPGRADE
ARGS
Buy
Las Vegas Sands upgraded on Macau outlook at Argus
As noted earlier, Argus upgraded Las Vegas Sands to Buy from Hold. Analyst John Staszak notes that Macau gross gaming revenue increased year-over-year last month for the first time in over two years. He says that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. Target $67.
10/04/16
BOFA
10/04/16
UPGRADE
Target $63
BOFA
Buy
Las Vegas Sands upgraded on expected estimate revisions at BofA/Merrill
BofA/Merrill analyst Shaun Kelley upgraded Las Vegas Sands to Buy and raised its price target to $63 from $52. The analyst said shares remain fairly under-owned and thinks estimate revisions will move higher due to market momentum, better ROI for Parisian, Cotai infrastructure additions, and optionality from Japan and real estate.
10/04/16
BOFA
10/04/16
UPGRADE
BOFA
Buy
Las Vegas Sands upgraded to Buy from Neutral at BofA/Merrill
09/14/16
09/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Macy's (M) upgraded to Buy from Neutral at Citi with analyst Paul Lejuez saying an attractive free cash flow and dividend yield makes the risk/reward attractive at current levels. 2. Fifth Third (FITB) upgraded to Buy from Neutral at Compass Point. 3. F5 Networks (FFIV) upgraded to Outperform from Perform at Oppenheimer with analyst Ittai Kidron saying the company has several potential drivers that could drive year-over-year product revenue growth back into positive territory in fiscal 2017. 4. Las Vegas Sands (LVS) upgraded to Buy from Hold at Argus with analyst John Staszak saying that Macau gambling is shifting towards the non-VIP market, where he believes that Las Vegas Sands is well-positioned. 5. DeVry (DV) upgraded to Outperform from Market Perform at Barrington with analyst Alexander Paris saying management's near-term goal is stabilizing revenue at DeVry University growing enrollment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
NFLX Netflix
$102.34

-0.29 (-0.28%)

09/27/16
JPMS
09/27/16
NO CHANGE
Target $125
JPMS
Overweight
Netflix price target raised to $125 from $116 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for Netflix to $125 on a roll forward to his 2017 estimates. The analyst keeps an Overweight rating on the shares. The target is for December 2017.
10/05/16
10/05/16
NO CHANGE

Bernstein sees no 'compelling rationale' for Apple buying Netflix
Bernstein analyst Toni Sacconaghi says he does not see a "compelling rationale" for Apple (AAPL) acquiring Netflix (NFLX). The steaming service has recently been the subject of takeover speculation, with Disney (DIS) mentioned as a possible suitor. Buying Netflix to run exclusively on Apple's operating service and AppleTV is "not a value-creating thesis and could not possibly justify a $50B price tag," Sacconaghi tells investors in a research note. Apple could buy Netflix and continue to run it as it does today, but that "would be highly out of character" for the iPhone maker, the analyst contends. Sacconaghi believes Apple could get much of the benefit of a services offering with much less upfront risk by partnering with Netflix, rather than acquiring it. He sees a partnership as more likely than a takeover. Further, Sacconaghi thinks a potential a partnership or acquisition by Apple does not justify owning Netflix since a deal is very hard to predict. The analyst has an Outperform rating on Apple and an Underpeform rating on Netflix. He has a $62 price target for Netflix shares. The streaming service closed yesterday down 29c to $102.34.
10/04/16
LOOP
10/04/16
INITIATION
LOOP
Buy
Netflix initiated with a Buy at Loop Capital
Loop Capital analyst David Miller initiated Netflix with a Buy and a $125 price target.
10/04/16
MUSA
10/04/16
NO CHANGE
MUSA
Netflix Q3 international subcriber adds likely to top consensus, says M Science
M Science analyst Corey Barrett, in a note published before the open, said he expects Netflix to report Q3 international subscriber additions of 2.18M, which is above the 2M subscriber consensus forecast. Previously, M Science said Netflix churn indications in July and August led it to set a domestic paid net subscriber addition estimate for Q3 of zero, below the Q3 consensus estimate of 351,000 and guidance of 400,000. Combining the two, the firm estimates Netflix will report Q3 global streaming subscriber additions of 2.08M, which is below the consensus estimate of 2.3M.
DB Deutsche Bank

09/19/16
FBCO
09/19/16
INITIATION
FBCO
Underperform
Deutsche Bank initiated with an Underperform at Credit Suisse
Credit Suisse analyst Jon Peace initiated Deutsche Bank with an Underperform saying the recent slow filing and capital shortfall will lower dividend expectations and keep shares under pressure.
09/19/16
09/19/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DSW (DSW) initiated with a Negative at Susquehanna. 2. Deutsche Bank (DB) initiated with an Underperform at Credit Suisse. 3. UBS (UBS) initiated with a Neutral at Credit Suisse. 4. Cerner (CERN) initiated with a Neutral at BofA/Merrill. 5. Callidus Software (CALD) reinstated with an Outperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
DoJ will not destabilize Deutsche Bank, says Cowen
Cowen analyst Jaret Seiberg sees little practical or political upside for the Justice Department to press Deutsche Bank for a penalty that is so large it could destabilize the bank and create a new financial crisis. He expects the penalty for violations related to mortgage-backed securities to be structured below the speculated $14B that seems to have alarmed the market. Seiberg adds both sides have incentives to reach a deal quickly.
09/30/16
09/30/16
NO CHANGE

Correction: Deutsche Bank credit upgraded to Neutral at BofA/Merrill
BofA/Merrill upgraded Deutsche Bank's credit to Neutral, not the equity.

TODAY'S FREE FLY STORIES

NVDQ

Novadaq

$6.59

-0.01 (-0.15%)

, CI

Cigna

$146.52

2.96 (2.06%)

15:57
02/21/17
02/21
15:57
02/21/17
15:57
Hot Stocks
LifeNet says Dermacell receives coverage from Cigna »

Cigna (CI) now covers…

NVDQ

Novadaq

$6.59

-0.01 (-0.15%)

CI

Cigna

$146.52

2.96 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

  • 28

    Feb

PBYI

Puma Biotechnology

$40.25

2.9 (7.76%)

15:56
02/21/17
02/21
15:56
02/21/17
15:56
Options
Puma Biotechnology put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Jul

SODA

SodaStream

$47.14

-0.53 (-1.11%)

15:54
02/21/17
02/21
15:54
02/21/17
15:54
Hot Stocks
Teleios Capital lowers stake in SodaStream to 4.5% »

Teleios Capital has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$27.00

0.2 (0.75%)

15:48
02/21/17
02/21
15:48
02/21/17
15:48
Hot Stocks
Matrix Partners China lowers stake in Momo to 12.6% from 15.4% »

On September 23, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

BMY

Bristol-Myers

$53.55

-1.04 (-1.91%)

15:38
02/21/17
02/21
15:38
02/21/17
15:38
Hot Stocks
Breaking Hot Stocks news story on Bristol-Myers »

Bristol-Myers up 2.5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

BMY

Bristol-Myers

$53.54

-1.05 (-1.92%)

15:38
02/21/17
02/21
15:38
02/21/17
15:38
Periodicals
Carl Icahn takes stake in Bristol-Myers, WSJ reports »

Icahn sees value in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

DEPO

Depomed

$16.47

-0.38 (-2.26%)

15:35
02/21/17
02/21
15:35
02/21/17
15:35
Options
Depomed options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

CSCO

Cisco

$33.74

0.14 (0.42%)

15:32
02/21/17
02/21
15:32
02/21/17
15:32
Conference/Events
Cisco to host service provider tech talk »

Cisco SVP Kanouff hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 03

    Mar

EFA

iShares MSCI EAFE Index Fund

$60.65

0.15 (0.25%)

15:31
02/21/17
02/21
15:31
02/21/17
15:31
Options
Defensive option play opened in the iShares MSCI EAFE Fund »

Defensive option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$16.96

0.1 (0.59%)

15:26
02/21/17
02/21
15:26
02/21/17
15:26
Options
Nuance call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRBP

Corbus Pharmaceuticals

$8.85

0.55 (6.63%)

15:25
02/21/17
02/21
15:25
02/21/17
15:25
Conference/Events
Cantor Fitzgerald health/pharma analysts hold analyst/industry conference call »

Analysts, along with Key…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 13

    Mar

$NSD

NASDAQ Market Internals

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENT

Global Eagle

$6.22

-0.01 (-0.16%)

15:21
02/21/17
02/21
15:21
02/21/17
15:21
Downgrade
Global Eagle rating change  »

Global Eagle downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 06

    Mar

ARLZ

Aralez

$4.50

-0.02 (-0.44%)

, AMGN

Amgen

$173.29

1.18 (0.69%)

15:20
02/21/17
02/21
15:20
02/21/17
15:20
Hot Stocks
Bass group fails to prove Aralez patent claims unpatentable »

The Coalition For…

ARLZ

Aralez

$4.50

-0.02 (-0.44%)

AMGN

Amgen

$173.29

1.18 (0.69%)

BIIB

Biogen

$288.94

-1.19 (-0.41%)

ABBV

AbbVie

$61.66

-0.1147 (-0.19%)

JNJ

Johnson & Johnson

$119.49

0.63 (0.53%)

SHPG

Shire

$181.08

2.38 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 24

    Feb

  • 06

    Mar

  • 07

    Mar

  • 09

    Mar

  • 14

    Mar

  • 17

    Mar

  • 21

    Mar

  • 27

    Mar

  • 01

    Apr

  • 26

    Jun

  • 19

    Jul

HCLP

Hi-Crush Partners

$21.58

0.275 (1.29%)

15:20
02/21/17
02/21
15:20
02/21/17
15:20
Options
Hi Crush options imply 9.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

TWTR

Twitter

$16.42

-0.2 (-1.20%)

15:18
02/21/17
02/21
15:18
02/21/17
15:18
Hot Stocks
Twitter head of entertainment talent resigns »

Lara Cohen, head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

KRP

Kimbell Royalty Partners

$19.90

0.15 (0.76%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Hot Stocks
Breaking Hot Stocks news story on Kimbell Royalty Partners »

Rivercrest Royalties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GT

Goodyear Tire

$36.07

-0.09 (-0.25%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Options
Goodyear Tire put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$20.11

-0.06 (-0.30%)

15:16
02/21/17
02/21
15:16
02/21/17
15:16
Conference/Events
Barrick Gold to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MARA

Marathon Patent Group

$1.34

-0.04 (-2.90%)

, HON

Honeywell

$124.79

0.2317 (0.19%)

15:15
02/21/17
02/21
15:15
02/21/17
15:15
Hot Stocks
Marathon Patent unit files patent infringement suits against Honeywell, Somfy »

Marathon Patent Group…

MARA

Marathon Patent Group

$1.34

-0.04 (-2.90%)

HON

Honeywell

$124.79

0.2317 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 01

    Mar

  • 29

    Mar

  • 24

    Apr

15:15
02/21/17
02/21
15:15
02/21/17
15:15
General news
Breaking General news story  »

San Francisco Federal…

RDS.A

Royal Dutch Shell

$52.48

0.275 (0.53%)

15:13
02/21/17
02/21
15:13
02/21/17
15:13
Conference/Events
Royal Dutch Shell to hold a conference call »

EVP of Gas and Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBYI

Puma Biotechnology

$40.25

2.9 (7.76%)

, RHHBY

Roche

$30.53

0.02 (0.07%)

15:11
02/21/17
02/21
15:11
02/21/17
15:11
Hot Stocks
Before the Move: Watch Puma Biotech into data on breast cancer rival »

Ahead of Roche's…

PBYI

Puma Biotechnology

$40.25

2.9 (7.76%)

RHHBY

Roche

$30.53

0.02 (0.07%)

IBB

iShares Nasdaq Biotechnology Index

$294.35

1.37 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 27

    Feb

  • 09

    Mar

  • 26

    Jun

  • 21

    Jul

XPO

XPO Logistics

$48.50

-0.72 (-1.46%)

15:05
02/21/17
02/21
15:05
02/21/17
15:05
Options
XPO Logistics options imply 10.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.